# Sanofi Type: Company Source: GetYourBrief — https://getyourbrief.com/entity/sanofi Canonical HTML page: https://getyourbrief.com/entity/sanofi ## Timeline - **2026-Q4**: Anticipated PDUFA — Expected deadline for the FDA's final approval decision. - **2026-07-16**: FDA Approves Lipfendra — The FDA approved Lipfendra (enlicitide), the first once-daily oral PCSK9 inhibitor, for adults with hypercholesterolemia including inherited forms, based on Phase 3 CORALreef trials showing 56-59% LDL-C reduction. - **2026-03-24**: Agreement Signed — Landmark FTA officially signed, initiating the ratification process. - **2026-02-18**: Regulatory Reversal — FDA agrees to review the application after Moderna addresses concerns. - **2026-01**: Refusal to File — FDA issues an RTF citing deficiencies in the initial application. - **2026**: Rollout Milestone — Acoziborole enters the final stages of regulatory rollout for endemic regions. - **2026**: Acoziborole Rollout — The first single-dose oral cure begins deployment, enabling 'screen-and-treat' strategies. - **2025-Q4**: BLA Submission — Moderna submits Biologics License Application for mRNA-1010. - **2025-01-15**: Strategic Pivot — Talks resume with a new focus on critical minerals and supply chain security. - **2023-10-29**: Talks Stall — Negotiations collapse in Osaka over agricultural quotas and geographic indications. - **2022**: Trial Results — Phase 2/3 clinical trial results for Acoziborole show high efficacy. - **2018-06-18**: Negotiations Launched — Formal trade talks begin in Canberra focusing on market access and IP. - **2018**: Fexinidazole Approval — First all-oral 10-day treatment for sleeping sickness is approved. - **2018**: Fexinidazole Approval — The first all-oral treatment is approved, requiring 10 days of pills taken with food. - **2009**: Research Begins — DNDi starts screening compounds for a single-dose HAT treatment. ## Recent coverage (11 stories, network-wide) ### New pill cuts LDL 59%: How Lipfendra could change cholesterol care for millions 2026-07-16 22:00:46 · Sector: health · Sentiment: Strongly positive · Impact: 9/10 · Sources: 132 The FDA approved the first oral PCSK9 inhibitor, Lipfendra, demonstrating a 59% LDL reduction in trials. The pill form removes injection barriers and is priced lower than existing injectables, potentially improving adherence and access for patients with high cholesterol. Full story: https://gethealthbrief.com/story/lipfendra-oral-pcsk9-lowers-ldl-59-percent-patient-access ### Merck’s oral PCSK9 inhibitor hits 59% LDL cut, leapfrogging injectable rivals 2026-07-16 22:00:10 · Sector: bio · Sentiment: Strongly positive · Impact: 9/10 · Sources: 132 Merck won FDA approval for Lipfendra, a small-molecule oral PCSK9 inhibitor that achieved 56-59% LDL-C reductions in Phase 3. This breakthrough in oral delivery challenges the dominance of injectable biologics from Amgen and Sanofi/Regeneron. Full story: https://getbiobrief.com/story/merck-lipfendra-fda-approval-oral-pcsk9-59-percent ### EU-Australia Free Trade Deal Unlocks New Pharma and MedTech Corridors 2026-03-24 14:06:32 · Sector: bio · Sentiment: Positive · Impact: 7/10 · Sources: 2 After eight years of complex negotiations, the European Union and Australia have signed a landmark free trade agreement aimed at eliminating regulatory barriers. The deal is set to streamline market access for European biologics while securing critical mineral supply chains essential for advanced medical manufacturing. Full story: https://getbiobrief.com/story/eu-australia-free-trade-agreement-pharma-impact ### Single-Dose Breakthrough: Acoziborole Signals End for Sleeping Sickness 2026-03-16 21:50:22 · Sector: bio · Sentiment: Strongly positive · Impact: 8/10 · Sources: 2 The introduction of acoziborole, the first single-dose oral treatment for Human African Trypanosomiasis (sleeping sickness), marks a pivotal shift in global health efforts. Developed through a non-profit partnership between DNDi and Sanofi, the drug offers a simplified path to disease elimination by 2030. Full story: https://getbiobrief.com/story/acoziborole-sleeping-sickness-breakthrough-2026 ### Single-Dose Breakthrough: Acoziborole Signals End of Sleeping Sickness 2026-03-16 21:44:53 · Sector: health · Sentiment: Strongly positive · Impact: 8/10 · Sources: 2 The introduction of Acoziborole, a single-dose oral medication, marks a pivotal shift in the global fight against Human African Trypanosomiasis. This breakthrough treatment simplifies complex therapeutic regimens, potentially enabling the total elimination of the disease by 2030. Full story: https://gethealthbrief.com/story/acoziborole-sleeping-sickness-elimination-2026 ### CDC Data Reveals Suboptimal Flu Vaccine Efficacy for 2025-2026 Season 2026-03-14 23:48:17 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Preliminary reports from US health officials indicate that this season's influenza vaccines provided lower-than-expected protection against circulating strains. The findings underscore the persistent challenge of viral mismatch and are expected to accelerate the industry's shift toward next-generation mRNA and recombinant vaccine technologies. Full story: https://getbiobrief.com/story/flu-vaccine-efficacy-decline-us-officials ### US Flu Vaccine Effectiveness Drops Below Historical Averages for 2025-26 Season 2026-03-14 23:47:43 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Preliminary CDC data indicates that the 2025-2026 influenza vaccine provided lower-than-expected protection, with effectiveness falling to approximately 32%. The findings highlight a significant mismatch between the vaccine's composition and the dominant H3N2 variant, sparking calls for faster manufacturing platforms. Full story: https://gethealthbrief.com/story/flu-vaccine-effectiveness-decline-2026 ### CDC Issues Global Travel Alerts as Polio Resurges in Tourist Hubs 2026-03-04 18:39:10 · Sector: bio · Sentiment: Negative · Impact: 7/10 · Sources: 2 The CDC has issued urgent travel advisories for several popular tourist destinations following a confirmed spread of poliovirus. This development signals a significant setback for global eradication efforts and is expected to drive a surge in demand for inactivated poliovirus vaccines (IPV). Full story: https://getbiobrief.com/story/cdc-polio-travel-advisories-2026 ### CDC Issues Travel Advisories for Tourist Hubs Amid Global Polio Resurgence 2026-03-04 18:36:27 · Sector: health · Sentiment: Negative · Impact: 7/10 · Sources: 2 The CDC has issued a series of travel notices for popular international tourist destinations following a spike in polio detections. The move signals a shift in global health security, requiring travelers to verify immunization status and potentially seek adult boosters before departure. Full story: https://gethealthbrief.com/story/cdc-polio-travel-advisories-2026 ### FDA Reverses Course, Agrees to Review Moderna’s mRNA Flu Vaccine 2026-02-19 00:58:25 · Sector: bio · Sentiment: Positive · Impact: 7/10 · Sources: 2 The FDA has rescinded its initial refusal to file Moderna’s Biologics License Application for its seasonal flu vaccine, mRNA-1010. This rare regulatory pivot clears the path for a formal review of the first mRNA-based influenza shot, a critical milestone for Moderna’s post-pandemic growth strategy. Full story: https://getbiobrief.com/story/fda-reverses-moderna-flu-vaccine-review ### FDA Reverses Stance on Moderna’s mRNA Flu Shot, Clearing Path for Review 2026-02-18 21:43:09 · Sector: finance · Sentiment: Positive · Impact: 7/10 · Sources: 3 The U.S. Food and Drug Administration has unexpectedly reversed its previous position, agreeing to review Moderna’s mRNA-based influenza vaccine candidate. This regulatory pivot marks a critical victory for Moderna as it seeks to diversify its portfolio beyond COVID-19 and challenge the traditional seasonal flu market. Full story: https://getfinancebrief.com/story/fda-reversal-moderna-mrna-flu-shot-review --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.